Search Result

Results for "

Ca2 mobilization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bombesin Receptor (1) Calcium Channel (3) Cannabinoid Receptor (1) CCR (3) Complement System (1) EBI2/GPR183 (2) ERK (1) Formyl Peptide Receptor (FPR) (1) Interleukin Related (1) JNK (1) Leukotriene Receptor (1) Melanocortin Receptor (3) mGluR (2) nAChR (1) Neuropeptide Y Receptor (3) Neurotensin Receptor (1) Prostaglandin Receptor (1) Protease Activated Receptor (PAR) (1) Reactive Oxygen Species (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Endocrinology (3) Inflammation/Immunology (11) Metabolic Disease (3) Neurological Disease (13)

By Targets:

Bombesin Receptor (1)

Calcium Channel (3)

Cannabinoid Receptor (1)

CCR (3)

Complement System (1)

EBI2/GPR183 (2)

ERK (1)

Formyl Peptide Receptor (FPR) (1)

Interleukin Related (1)

JNK (1)

Leukotriene Receptor (1)

Melanocortin Receptor (3)

mGluR (2)

nAChR (1)

Neuropeptide Y Receptor (3)

Neurotensin Receptor (1)

Prostaglandin Receptor (1)

Protease Activated Receptor (PAR) (1)

Reactive Oxygen Species (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (2)

Endocrinology (3)

Inflammation/Immunology (11)

Metabolic Disease (3)

Neurological Disease (13)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: CRAC Channel

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16639

ML314	Neurotensin Receptor	Neurological Disease Endocrinology
ML314 is a potent molecule agonist of NTR1 (EC₅₀ = 1.9 μM); showed good selectivity against NTR2 and GPR35, but does not stimulate Ca ²⁺ mobilization.

HY-P1250

RFRP-3(human) Neuropeptide VF(124-131)(human)	Neuropeptide Y Receptor	Neurological Disease
RFRP-3 (Neuropeptide VF(124-131))(human), a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca ²⁺?mobilization. RFRP-3(human) is a NPFF1?receptor agonist, it inhibits forskolin-induced production of cAMP with an IC₅₀ of 0.7 nM .

HY-100402

CFMTI	mGluR	Cancer
CFMTI inhibits L-glutamate-induced intracellular Ca ²⁺ mobilization in CHO cells expressing human and rat mGluR1a, with IC₅₀s of 2.6 and 2.3 nM, respectively .

HY-103472

FPR-A14	Formyl Peptide Receptor (FPR)	Neurological Disease
FPR-A14 is a potent formyl peptide receptor (FPR) agonist. FPR-A14 is a potent activator of neutrophil Ca ²⁺ mobilization and chemotaxis with EC₅₀s of 630 nM and 42 nM, respectively. FPR-A14 induces cell differentiation .

HY-163796

GPR183-IN-2	EBI2/GPR183	Neurological Disease Inflammation/Immunology Cancer
GPR183-IN-2 (compound 23) is a potent GPR183 inhibitor. GPR183-IN-2 inhibits Ca ²⁺ mobilization with an IC₅₀ value of 39.45 nM. GPR183-IN-2 has the potential for the research of cancer, autoimmune diseases, pain, and osteoporosis .

HY-147301

Resomelagon AP1189	Melanocortin Receptor	Metabolic Disease Inflammation/Immunology
Resomelagon (AP1189) is a potent, orally active melanocortin receptor (MR) agonist about MC₁ and MC₃. Resomelagon induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon has anti-inflammatory activity. Resomelagon can be used for obesity and chronic inflammation research .

HY-120985

Araguspongin B	Others	Neurological Disease
Xestospongins and araguspongins are marine natural products first isolated from Pacific basin sponges, and noted to have vasodilatory properties.1 Inositol phosphates (IP) are important signal transduction messengers acting via IP3 receptors to promote the mobilization of Ca2+ from intracellular stores.2 Araguspongin B antagonizes the calcium-releasing action of inositol 1,4,5-trisphosphate at the receptor level in cerebral microsomes, with an IC₅₀ of 0.6 μM. It is nearly as potent as xestospongin C as an antagonist of the IP3 receptor.

HY-P1250A

RFRP-3(human) TFA Neuropeptide VF(124-131)(human) TFA	Neuropeptide Y Receptor	Neurological Disease
RFRP-3 (Neuropeptide VF(124-131))(human) TFA, a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca ²⁺?mobilization. RFRP-3(human) is a NPFF1?receptor agonist, it inhibits forskolin-induced production of cAMP with an IC₅₀ of 0.7 nM .

HY-116723

CFMMC	mGluR	Neurological Disease
CFMMC is a selective allosteric metabotropic glutamate receptor 1 (mGluR1) antagonist. CFMMC inhibits L-glutamate-induced intracellular Ca ²⁺ mobilization ([Ca ²⁺]i) in Chinese hamster ovary cells expressing recombinant human mGluR1a with an IC₅₀ value of 50 nM. CFMMC is promising for research of various central nervous system disorders, such as schizophrenia, epilepsy, anxiety, pain, cognitive dysfunction and drug abuse .

HY-130358

PDDHV	Calcium Channel	Neurological Disease
PDDHV is a calcium absorption inducer and may achieve 45Ca ²⁺ influx by stimulating vanillic acid receptor VR1. PDDHV induces 45Ca ²⁺ uptake (EC₅₀: 70 nM) in rat dorsal root ganglion neurons (expressing native vanilloid receptors) and calcium mobilization (EC₅₀: 125 nM) in VR1-transfected CHO cells. PDDHV also inhibits [3H]-resiniferatoxin (RTX) binding to the dorsal root ganglion membrane in rats .

HY-147301A

Resomelagon acetate AP1189 acetate	Melanocortin Receptor	Metabolic Disease Inflammation/Immunology
Resomelagon (AP1189) acetate is a potent, orally active melanocortin receptor (MR) agonist about MC₁ and MC₃. Resomelagon acetate induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon acetate has anti-inflammatory activity. Resomelagon acetate can be used for obesity and chronic inflammation research .

HY-112741

SB-209247	Leukotriene Receptor	Inflammation/Immunology
SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a K_i of 0.78 nM. SB-209247 blocks LTB4-induced Ca ²⁺ mobilization with an IC₅₀ of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .

HY-163795

GPR183-IN-1	EBI2/GPR183	Neurological Disease Inflammation/Immunology Cancer
GPR183-IN-1 (compound 15) is a potent and orally activity GPR183 inhibitor. GPR183-IN-1 inhibits Ca ²⁺ mobilization with an IC₅₀ value of 39.97 nM. GPR183-IN-1 has the potential for the research of cancer, autoimmune diseases, pain, and osteoporosis .

HY-P1437A

Neuropeptide S(Mouse) TFA	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC₅₀=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca ²⁺. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.

HY-150135B

D-myo-Inositol 1,4,5-trisphosphate tripotassium 1 Publications Verification Inositol 1,4,5-trisphosphate tripotassium; Ins(1,4,5)-P3 tripotassium	Calcium Channel	Neurological Disease
D-myo-Inositol 1,4,5-trisphosphate tripotassium, a second messenger, elicits *Ca ²⁺* mobilization. D-myo-Inositol 1,4,5-trisphosphate tripotassium inhibits the binding of phosphoinositide-specific phospholipase C-delta 1 (PLC-delta 1) to bilayer membranes composed of phosphatidylcholine (PC) and phosphatidylinositol 4,5-bisphosphate (PIP2) .

HY-157453

CCR4 antagonist 4	CCR	Inflammation/Immunology
CCR4 antagonist 4 (compound 22) is a selective and potent antagonist of the CC chemokine receptor-4 (CCR4), with an IC₅₀ of 0.02 μM. CCR4 antagonist 4 also blocks MDC-mediated chemotaxis (IC₅₀: 0.007 μM) and Ca ²⁺ mobilization (IC₅₀: 0.003 μM). CCR4 antagonist 4 can be used for allergic inflammation research .

HY-147301B

Resomelagon methanesulfonate AP1189 methanesulfonate	Melanocortin Receptor ERK	Inflammation/Immunology
Resomelagon methanesulfonate (AP1189 methanesulfonate) is the methanesulfonate salt form of Resomelagon (HY-147301). Resomelagon methanesulfonate is an orally active melanocortin receptor (MR) agonist. Resomelagon methanesulfonate induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon methanesulfonate exhibits anti-inflammatory activity in mouse peritonitis and peritonitis model. Resomelagon methanesulfonate can be used for obesity and chronic inflammation research .

HY-14350

AC-55541 1 Publications Verification	Protease Activated Receptor (PAR)	Others
AC-55541 is a highly selective protease-activated receptor 2 (PAR2) agonist (pEC₅₀=6.7), displays no activity at other PAR subtypes or at over 30 other receptors involved in nociception and inflammation. AC-55541 has pEC₅₀ values of 5.9 and 6.6 in PI hydrolysis assays and Ca ²⁺ mobilization assays and exhibits pronociceptive activity in vivo .

HY-145196

RTICBM-189	Cannabinoid Receptor	Neurological Disease
RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB₁) receptor with a pIC₅₀ of 7.54 in Ca ²⁺ mobilization assay. RTICBM-189 has pIC₅₀s of 5.29 and 6.25 for hCB₁ and mCB₁, respectively. RTICBM-189 significantly and selectively attenuates the reinstatement of the addictive agent-seeking behavior in rats .

HY-16992A

W-54011 4 Publications Verification	Complement System Reactive Oxygen Species	Inflammation/Immunology
W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of ¹²⁵I-labeled C5a to human neutrophils with a K_i value of 2.2 nM. W-54011 also inhibits C5a-induced intracellular Ca ²⁺ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC₅₀s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively .

HY-133011

nAChR agonist 1	nAChR	Neurological Disease
nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC₅₀ of 0.32 µM in a Ca ²⁺ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .

HY-N7690

3,5,7,3′,4′-Pentamethoxyflavone	Calcium Channel	Cardiovascular Disease Metabolic Disease
3,5,7,3’,4’-Pentamethoxyflavone is a Ca ²⁺ channel inhibitor. 3,5,7,3’,4’-Pentamethoxyflavone can protect DNA from oxidative damage. 3,5,7,3’,4’-Pentamethoxyflavone can induce relaxation of the human corpus cavernosum through calcium mobilization-related mechanisms. 3,5,7,3’,4’-Pentamethoxyflavone can promote the expression of eNOS and cystathionine gamma lyase CSE proteins in middle-aged male rats and regulate vascular function. 3,5,7,3’,4’-Pentamethoxyflavone can be used in research related to diabetes and cardiovascular diseases .

HY-15724

Vercirnon 2 Publications Verification GSK-1605786; CCX282-B; Traficet-EN	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 µM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-15724A

Vercirnon sodium 2 Publications Verification GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 µM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer

Cat. No.	Product Name	Target	Research Area